Skip to Content

CLL – The impact of using ibrutinib as front-line treatment

This is the first study to use real-world evidence to describe and compare the time to the next treatment outcomes between ibrutinib and acalabrutinib in patients with treatment-naïve CLL. In this MEDtalk Ryan Jacobs, Atrium Health Levine Cancer Institute, presents the data.

Ryan Jacobs

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top